ION Beam Application (IOBCF) 46.0500 $IOBCF
Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Opportunities
M2 - Fri Dec 11, 3:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/7qtv88/spondyloarthritis) has announced the addition of the "Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report, Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015" provides an overview of Spondyloarthritis (Spondyloarthropathy) clinical trials scenario. This report provides top line data relating to the clinical trials on Spondyloarthritis (Spondyloarthropathy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Merck & Co., Inc. - AbbVie Inc. - Johnson & Johnson - Vianex S.A. - Sint Maartenskliniek - Laboratoires Stella SA - Ion Beam Applications S.A. - Given Imaging Ltd. - Abbott Laboratories For more information visit http://www.researchandmarkets.com/research/7q...oarthritis
JNJ: 122.85 (+0.34), ABT: 41.89 (+0.53), MRK: 59.35 (+0.57), ABBV: 64.16 (+0.73)
IBA Signs Formal Contract to Install the First Proton Therapy Center in The Netherlands
CNW Group - Thu Apr 23, 5:24AM CDT
IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has signed a formal contract with the University Medical Center Groningen (UMCG) to establish the first proton therapy center in The Netherlands, in Groningen.
IBA and Toshiba Sign Strategic Partnership in Particle Therapy
CNW Group - Thu Apr 09, 12:18PM CDT
IBA (Ion Beam Applications S.A.) and Toshiba Corporation (Tokyo: 6502) today announce the signing of a global collaboration to expand access to advanced particle therapy worldwide. Toshiba Medical Systems Corporation will become the distributor in Japan for Proteus(®)ONE, IBA's compact single-room proton therapy solution, and IBA will become the agent for Toshiba's Carbon Therapy Solutions outside Japan.
Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Opportunities
M2 - Fri Dec 11, 3:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/7qtv88/spondyloarthritis) has announced the addition of the "Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report, Spondyloarthritis (Spondyloarthropathy) Global Clinical Trials Review, H2, 2015" provides an overview of Spondyloarthritis (Spondyloarthropathy) clinical trials scenario. This report provides top line data relating to the clinical trials on Spondyloarthritis (Spondyloarthropathy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Merck & Co., Inc. - AbbVie Inc. - Johnson & Johnson - Vianex S.A. - Sint Maartenskliniek - Laboratoires Stella SA - Ion Beam Applications S.A. - Given Imaging Ltd. - Abbott Laboratories For more information visit http://www.researchandmarkets.com/research/7q...oarthritis
JNJ: 122.85 (+0.34), ABT: 41.89 (+0.53), MRK: 59.35 (+0.57), ABBV: 64.16 (+0.73)
IBA Signs Formal Contract to Install the First Proton Therapy Center in The Netherlands
CNW Group - Thu Apr 23, 5:24AM CDT
IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has signed a formal contract with the University Medical Center Groningen (UMCG) to establish the first proton therapy center in The Netherlands, in Groningen.
IBA and Toshiba Sign Strategic Partnership in Particle Therapy
CNW Group - Thu Apr 09, 12:18PM CDT
IBA (Ion Beam Applications S.A.) and Toshiba Corporation (Tokyo: 6502) today announce the signing of a global collaboration to expand access to advanced particle therapy worldwide. Toshiba Medical Systems Corporation will become the distributor in Japan for Proteus(®)ONE, IBA's compact single-room proton therapy solution, and IBA will become the agent for Toshiba's Carbon Therapy Solutions outside Japan.
